试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-15
SHIFT: Studying HIV Immunology After Fecal Transplant
编号:NCT03163784登记状态:入组前撤回企业 / 申办者:Massachusetts General Hospital
药物 / 成分:Fecal Inoculum Capsule、Placebo (for Fecal Inoculum Capsule)、Antibiotic、Antibiotic Placebo
登记的停止原因(原文):The study closed because of shifting research priorities and interests.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-15
Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus
编号:NCT03502694登记状态:入组前撤回企业 / 申办者:Janssen Research & Development, LLC
药物 / 成分:Lumicitabine、Placebo
登记的停止原因(原文):sponsor decision
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-15
A Study of Atezolizumab in Combination With Bevacizumab in Untreated Locally Advanced or Metastatic Clear Cell or Non-Clear Cell Renal Cell Carcinoma
编号:NCT03693573登记状态:入组前撤回企业 / 申办者:Hoffmann-La Roche
药物 / 成分:Atezolizumab、Bevacizumab
登记的停止原因(原文):In the context of the ongoing evaluation of our data, we have determined that there is no need to generate additional safety data at this time in the 1L mRCC pa
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
SCH 66336 Before Surgery in Treating Patients With Colorectal Cancer That Has Metastasized to the Liver
编号:NCT00005030登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:SCH 66336、conventional surgery
登记的停止原因(原文):No enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
Arsenic Trioxide in Treating Patients With Chronic Phase Chronic Myelogenous Leukemia That Has Not Responded to Previous Treatment
编号:NCT00006091登记状态:入组前撤回企业 / 申办者:M.D. Anderson Cancer Center
药物 / 成分:arsenic trioxide
登记的停止原因(原文):No enrollment.
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
Effects of Berberine Hydrochloride and Bifidobacterium in Prediabetes Prevention and Treatment
编号:NCT02082756登记状态:入组前撤回企业 / 申办者:Xijing Hospital
药物 / 成分:Bifidobacterium viable pharmaceutics、Berberine Hydrochloride
登记的停止原因(原文):The sponsor have not enough money to support this trial
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
Effects of Berberine Hydrochloride and Bifidobacterium in Diabetes Mellitus Prevention and Treatment
编号:NCT02084004登记状态:入组前撤回企业 / 申办者:Xijing Hospital
药物 / 成分:Bifidobacterium viable pharmaceutics、Berberine Hydrochloride
登记的停止原因(原文):The sponsor have not enough money to support this trial
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
The Bioavailability of a Spray Dried Dispersion Solid Dose Formulation of PF-06260414 Relative to a Suspension Formulation
编号:NCT02393807登记状态:入组前撤回企业 / 申办者:Pfizer
药物 / 成分:PF 06260414 solid dose formulation、PF-06260414 nanosuspension
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
Etoposide, Prednisone, Vincristine Sulfate, Cyclophosphamide, and Doxorubicin Hydrochloride With Asparaginase in Treating Patients With Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
编号:NCT02538926登记状态:入组前撤回企业 / 申办者:University of Washington
药物 / 成分:Asparaginase、Cyclophosphamide、Doxorubicin Hydrochloride、Etoposide
登记的停止原因(原文):Drugs unavailable
查看官方原始记录 ↗试验撤回ClinicalTrials.gov(美国登记平台)来源日期:2018-11-14
Perioperative Chemotherapy With Bevacizumab for Colorectal Carcinomatosis French Part of the Main Bev-IP Study
编号:NCT03161041登记状态:入组前撤回企业 / 申办者:Hospices Civils de Lyon
药物 / 成分:Cytoreductive surgery combined with HIPEC、bevacizumab and HIPEC (Oxaliplatin 360 mg/m2).
登记的停止原因(原文):CHU Lyon will join as a participating center (and as national French coordinator) as a part of the BEV-IP study ongoing study EudraCT-number 2014-004257-14.
查看官方原始记录 ↗